Menu
No results found.
MOB
Moberg Pharma AB (publ) – STO
Weekly Share Price & Valuation Overview
Market Overview
Open
9.1550
Close
8.8500
High
9.3850
Low
8.3050
Trend
0.33191
Moberg Pharma AB (publ)
Sweden
• STO - Nasdaq Stockholm
• MOB
• Currency: SEK
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
Key strengths
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- SEK 401.86M
- Enterprise Value Operating value: market cap + total debt − cash.
- SEK 150.46M
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- SEK 12.35M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- SEK 7.36M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- SEK 0.26
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -6.60
- Shares Outstanding
- 47.00M
- Float Shares
- 41.80M
- Implied Shares Outstanding
- 47.00M
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. EBITDA suppressed where implausible vs revenue. Margins reflect latest TTM calculations.
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-2.71%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
59.64%
- ROA Return on assets: net income ÷ total assets.
-
-24.37%
- ROE Return on equity: net income ÷ shareholder equity.
-
-31.67%
Growth
Growth rates are YoY unless labeled QoQ.
- Revenue Growth Year-over-year revenue growth.
-
-12.50%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
30.00%
Liquidity & Solvency
Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 9.36
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.49
- Total Cash Cash and equivalents.
- SEK 254.75M
- Total Debt Short + long-term interest-bearing debt.
- SEK 3.35M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- SEK -251.39M
Cash Flow
Shown only when internally consistent; margins are TTM.
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- SEK -13.61M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-110.21%
Sharemaestro House View
Confidence: 1
Sharemaestro internal conviction (0–3, higher is better).
Risk: 2
Sharemaestro internal risk profile (0–3, higher is safer).
Operational: 3
Operational quality/consistency (0–3, higher is better).
Composite Score: 1
Overall internal composite (0–3, higher is better).
Suggested Allocation: 1.67%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
88.9%
Insiders
Shares held by company insiders (officers, directors).
10.7%
Institutions
Shares held by institutions (funds, pensions).
15.7%
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
None detected
Net Debt
Total debt − cash (negative = net cash).
SEK -251.39M
-2036.1% of revenue
Net debt relative to revenue — debt load vs business scale.
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
100
Methodology Notes
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
As of: 2025-08-18 10:13
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.
AI generated insights not available yet. Sign in to generate the snapshot.